Skip to content

Lung B.A.S.E.S. 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Ages 40-54

Lung B.A.S.E.S 4 Life Mobile Low-dose Computed Tomography (LDCT) Screening: Assessing Incidence and Stage of Lung Cancer Diagnosis in Subjects Ages 40-54 With a 30 Pack Year History or More Within North and South Carolina

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04577599
Enrollment
1160
Registered
2020-10-08
Start date
2021-01-07
Completion date
2028-10-01
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung Cancer, Lung Neoplasms

Keywords

Screening, Lung Cancer, Smoking

Brief summary

Low-dose CT Screening has been shown in two large trials in the United States (NLST) and Europe (NELSON) to increase overall survival in subjects 55 years of age and older with a strong smoking history. Unfortunately, in both North Carolina (NC) and South Carolina (SC), subjects are found to have the above referenced smoking history prior to reaching the minimum age in these studies. This study is aimed at decreasing the minimum age of screening in a high-risk population.

Detailed description

The primary objective of this study is to evaluate the lung cancer diagnosis rate in individuals 40-54 years of age at their first screening (T0) with mobile low-dose CT. Secondary objectives include evaluating the lung cancer diagnosis rate in individuals 40-54 years of age at subsequent screening visits (T1 and T2); evaluating the positive screening rate at T0, T1, and T2; evaluating the impact of baseline demographic (including insurance status), socioeconomic, and healthcare-related factors on lung cancer rates and positive screening rates; and summarizing the incidence rate of all types of cancer found with low-dose lung CT during lung cancer screening. Enrollment will continue until 174 subjects are identified in the evaluable population with a total of 1160 subjects anticipated to be enrolled and screened.

Interventions

OTHERMobile Low-dose Computed Tomography (LDCT) Screening

Low Dose CT Scan of the Chest

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER
Leon Levine Foundation
CollaboratorUNKNOWN

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to 54 Years
Healthy volunteers
Yes

Inclusion criteria

* Subject must meet all the following applicable inclusion criteria to participate in this study: 1. Written informed consent and HIPAA authorization for release of personal health information. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. 2. Age 40-54 years at the time of consent. 3. A positive smoking history of greater/equal to 30 pack years and they are either currently smoking or have quit within the last 15 years. 4. Ability to read and understand the English and/or Spanish language. 5. Ability to understand and comply with study procedures for the entire length of the study.

Exclusion criteria

* Subjects meeting any of the criteria below may not participate in the study: 1. Known diagnosis of lung cancer in the past 5 years. 2. Any known contraindication to having a low-dose CT Scan. 3. Known pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Lung cancer diagnosis rate in individuals 40-54 years of age at their first screening (T0) with mobile low-dose CT.1 dayThe lung cancer diagnosis variable will be determined for each subject as a binary variable indicating whether or not the subject's T0 screening results in a diagnosis of lung cancer.

Secondary

MeasureTime frameDescription
Lung cancer diagnosis rate in individuals 40-54 years of age at subsequent screening visits (T1 and T2)up to 24 monthsThe lung cancer diagnosis variable will be determined for each subject as a binary variable indicating whether or not the subject's T1 and T2 screening results in a diagnosis of lung cancer.
Positive screening rate at T0, T1, and T2up to 24 monthsThe positive screening variable at T0, T1 and at T2 will be determined for each subject as a binary variable indicating whether or not the subject's screening results indicate a Lung RADS of 3 or 4.
Impact of baseline demographic (including insurance status), socioeconomic, and healthcare-related factors on lung cancer rates and positive screening ratesup to 24 monthsAll binary outcomes will be analyzed using logistic regression models to evaluate the impact of baseline demographic, socioeconomic, and health care-related factors.
Incidence rate of all types of cancer found with low-dose lung CT during lung cancer screeningup to 24 monthsIncidental cancer diagnosis resulting from LDCT scan findings at T0, at T1, and at T2 will be captured for each subject including binary value of yes vs no for other cancer diagnosis, diagnosis date, type of cancer, and stage of disease.

Countries

United States

Contacts

CONTACTDarcy Doege, RN
Darcy.Doege@atriumhealth.org913-424-6431
PRINCIPAL_INVESTIGATORDaniel Carrizosa, MD

LCI

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 14, 2026